EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Proof-of-concept study exploring the effect of spesolimab in patients with moderate-to-severe hidradenitis suppurativa: a randomized double-blind placebo-controlled clinical trial

Afsaneh Alavi, Errol P Prens, Alexa B Kimball, John W Frew, James G Krueger, Sutirtha Mukhopadhyay, Heli Gao, Usha Ranganathan, Nathalie B Ivanoff, Ana C Hernandez Daly, Christos C Zouboulis iD

British Journal of Dermatology · 2024

DOI: 10.1093/bjd/ljae144 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Dermatology, 2024. Verfasst von Afsaneh Alavi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Mayo Clinic, Rochester, MN, USA. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa, Proof of Concept Study, Severity of Illness Index. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Boehringer Ingelheim.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with a considerable disease burden. Existing treatment options are limited and often suboptimal; a high unmet need exists for effective targeted therapies.

Objectives

To explore the effects of spesolimab treatment in patients with HS.

Methods

This randomized double-blind placebo-controlled proof-of-clinical-concept (PoCC) study was conducted at 25 centres across 12 countries from 3 May 2021 to 21 April 2022. Patients had moderate-to-severe HS for ≥ 1 year before enrolment. Patients were randomized (2 : 1) to receive a loading dose of 3600-mg intravenous spesolimab (1200 mg at weeks 0, 1 and 2) or matching placebo, followed by maintenance with either 1200-mg subcutaneous spesolimab every 2 weeks from weeks 4 to 10 or matching placebo. The primary endpoint was the percentage change from baseline in total abscess and inflammatory nodule (AN) count at week 12. Secondary endpoints were the absolute change from baseline in the International Hidradenitis Suppurativa Severity Score System (IHS4), percentage change from baseline in draining tunnel (dT) count, the proportion of patients achieving a dT count of 0, absolute change from baseline in the revised Hidradenitis Suppurativa Area and Severity Index (HASI-R), the proportion of patients achieving Hidradenitis Suppurativa Clinical Response (HiSCR50), the proportion of patients with ≥ 1 flare (all at week 12) and patient-reported outcomes.

Results

In this completed trial, randomized patients (n = 52) received spesolimab (n = 35) or placebo (n = 17). The difference vs. placebo in least squares mean is reported. At week 12, the percentage change in total AN count was similar between treatment arms: –4.1% [95% confidence interval (CI) –31.7 to 23.4]. There was greater numerical improvement in the spesolimab arm, as measured by IHS4 (13.9, 95% CI –25.6 to –2.3); percentage change from baseline in dT count (–96.6%, 95% CI –154.5 to –38.8); and the proportion of patients achieving a dT count of 0 (18.3%, 95% CI –7.9 to 37.5). Spesolimab treatment also improved HASI-R and HiSCR50 vs. placebo. Spesolimab demonstrated a favourable safety profile, similar to that observed in trials in other diseases.

Conclusions

This exploratory PoCC study supports the development of spesolimab as a new therapeutic option in HS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hidradenitis SuppurativaProof of Concept StudySeverity of Illness IndexHumansDouble-Blind MethodMaleFemaleAdultMiddle AgedTreatment OutcomeInjections, SubcutaneousDrug Administration ScheduleYoung Adult

Autor:innen und Institutionen

  • Department of Dermatology, Mayo Clinic, Rochester, MN, USA.
  • Department of Dermatology, Erasmus University Medical Center, Rotterdam, the Netherlands.
  • Harvard Medical School, Boston, MA, USA.
  • School of Clinical Medicine, UNSW Medicine and Health, Sydney, NSW, Australia.
  • Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY, USA.
  • Boehringer Ingelheim International GmbH, Ingelheim Am Rhein, Germany.

ORCID-Profile: Christos C Zouboulis

Förderung

  • Boehringer Ingelheim

Zitieren

APA

Alavi, A., Prens, E. P., Kimball, A. B., Frew, J. W., Krueger, J. G., Mukhopadhyay, S., Gao, H., Ranganathan, U., Ivanoff, N. B., Hernandez Daly, A. C., & Zouboulis, C. C. (2024). Proof-of-concept study exploring the effect of spesolimab in patients with moderate-to-severe hidradenitis suppurativa: a randomized double-blind placebo-controlled clinical trial. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljae144

Vancouver

Alavi A, Prens EP, Kimball AB, Frew JW, Krueger JG, Mukhopadhyay S, et al. Proof-of-concept study exploring the effect of spesolimab in patients with moderate-to-severe hidradenitis suppurativa: a randomized double-blind placebo-controlled clinical trial. British Journal of Dermatology. 2024. doi:10.1093/bjd/ljae144

BibTeX
@article{Alavi2024,
  author = {Alavi, Afsaneh and Prens, Errol P and Kimball, Alexa B and Frew, John W and Krueger, James G and Mukhopadhyay, Sutirtha and Gao, Heli and Ranganathan, Usha and Ivanoff, Nathalie B and Hernandez Daly, Ana C and Zouboulis, Christos C},
  title = {Proof-of-concept study exploring the effect of spesolimab in patients with moderate-to-severe hidradenitis suppurativa: a randomized double-blind placebo-controlled clinical trial},
  journal = {British Journal of Dermatology},
  year = {2024},
  doi = {10.1093/bjd/ljae144}
}
Kostenlos starten →